Thymogen

What Is Thymogen?

Thymogen is the dipeptide L-glutamyl-L-tryptophan, a two-residue immunomodulatory peptide originally identified in calf thymus extract. Researchers isolated the molecule from the natural thymic peptide complex thymalin using reverse-phase high-performance liquid chromatography, then synthesized it and designed a pharmaceutical preparation around it.^[1]

The compound carries the international nonproprietary name oglufanide and is also written as Glu-Trp, EW dipeptide or H-Glu-Trp-OH. It belongs to the group often called short peptide bioregulators, which also includes molecules such as vilon (Lys-Glu) and epitalon (Ala-Glu-Asp-Gly).

Most published work on Thymogen falls into four areas: immune and aging studies in rats, tissue-repair models in rabbits and rats, stereochemistry studies in mice, and chemistry work aimed at improving the dipeptide’s poor membrane permeability. Human clinical data are not represented in the abstracts reviewed for this page.

Chemical Structure and Molecular Identity

Thymogen is a linear dipeptide of L-glutamic acid and L-tryptophan with a free amino terminus and a free carboxyl terminus. PubChem (CID 100094) lists the molecular formula C16H19N3O5, a molecular weight of 333.34 g/mol and the InChIKey LLEUXCDZPQOJMY-AAEUAGOBSA-N. The primary CAS number is 38101-59-6; PubChem also lists 122933-59-9 among the compound’s registry numbers.

The molecule is highly polar, with a computed XLogP of -2.7, because the glutamyl side chain and the C-terminus both carry carboxylic acid groups. A 2008 study described L-Glu-L-Trp as a hydrophilic compound with low membrane permeability, which limits its passage across intestinal cells.^[2]

Isomers and related molecules

Stereochemistry matters for this dipeptide. A mouse study compared all four optical isomers (L-L, L-D, D-L and D-D) of alpha-linked Glu-Trp, along with gamma-linked analogs, and found that their effects on bone marrow stem cells depended on the optical orientation of glutamic acid and the type of peptide bond.^[3] Thymogen corresponds to the L-L, alpha-linked form. The gamma-glutamyl isomer and the reversed sequence Trp-Glu are distinct compounds.

The tryptophan indole ring also makes the molecule a target for synthetic chemistry. A 2023 paper used oglufanide as a substrate to demonstrate metal-free, site-selective C7-H borylation of tryptophan in finished peptides.^[4]

Research History and Development

Thymogen emerged from work on thymus-derived peptide extracts, when L-Glu-L-Trp was identified as an active component of the thymalin complex. A 2000 paper by Anisimov, Khavinson and Morozov describes this isolation and the subsequent design of a pharmaceutical containing the synthetic dipeptide.^[1]

Later research moved in several directions. A gerontology review compared thymic peptides, including thymalin and Thymogen, with pineal peptides and concluded that the pineal peptides had the stronger effect on age-related thymus involution than the thymic peptides had on pineal involution.^[5]

Medicinal chemists also tried to address the dipeptide’s poor oral uptake. In the 2008 study, researchers built a library of Glu-Trp derivatives carrying lipoamino acid or sugar groups and tested their stability and permeability in Caco-2 intestinal cell models before an initial rat absorption experiment.^[2] More recent work has produced analogs with an added D-alanine residue at either terminus.^[6]

A parallel line of research examined tissue repair. A 2015 rabbit study compared the sodium salt of Glu-Trp with an acylated version of the same dipeptide in chronic skin wounds and reported that acylation improved the dipeptide’s healing performance. That study, and the 2023 liver-injury work with D-alanine analogs, show a shift from the original immune and aging questions toward structure-activity comparisons between Thymogen and modified derivatives.^[7][6]

Mechanisms Studied in Research

Research attributes Thymogen’s activity mainly to effects on T cells and neutrophils, with later studies adding matrix metalloproteinase and antioxidant measures. The original characterization reported that the dipeptide activated T-cell differentiation and T-cell recognition of peptide-MHC complexes, changed intracellular cyclic nucleotide levels, and activated neutrophil chemotaxis and phagocytosis.^[1]

• Matrix metalloproteinases: in a rabbit chronic wound model, the sodium salt of Glu-Trp and an acylated analog lowered MMP-9, MMP-8 and MMP-2 activity in the early inflammatory phase and raised MMP-9, MMP-8 and MMP-1 activity during remodeling.^[7]
• Oxidative stress: in a rat model of carbon tetrachloride liver injury, Thymogen and its analogs suppressed lipid peroxidation, measured by malondialdehyde, and counteracted the drop in catalase activity.^[6]
• Stem cell responses: in mice, L-glutamyl isomers were inert toward committed bone marrow colony-forming units, while D-glutamyl isomers inhibited them.^[3]

None of these studies identified a specific receptor for the dipeptide. The available abstracts describe downstream cellular effects rather than a defined molecular binding target.

Key Findings From Published Studies

Published findings on Thymogen come from animal models and laboratory systems; the reviewed abstracts include no controlled human trials. The main results are summarized below by model.

Aging and spontaneous tumors in rats

In a study of 76 outbred female rats given long-term treatment with L-Glu-L-Trp or saline and followed until natural death, mean lifespan did not differ between groups. The longest-lived 10% of treated rats, however, survived 1,048 days on average versus 949 days in controls, and the Gompertz aging-rate parameter was lower in the treated group. Total tumor incidence was 1.5 times lower, malignant tumor incidence 1.7 times lower, and leukemias and lymphomas 3.4 times lower in treated rats.^[1]

Wound healing in rabbits

In a rabbit model of nonhealing dermal wounds, assessed by wound closure, zymography and histology, both Glu-Trp-ONa and its acylated analog shortened healing time compared with saline and with a reference wound-healing agent. Histology showed more granulation tissue and re-epithelialization, and the acylated analog performed better than the parent dipeptide.^[7]

Liver injury in rats

In acute carbon tetrachloride hepatopathy, Thymogen stimulated hepatocyte regeneration and reduced oxidative markers. Analogs with D-alanine added to the molecule produced stronger hepatotropic and antioxidant effects than Thymogen itself, with the C-terminal addition performing best.^[6]

Absorption and stability

Several lipid and sugar conjugates of Glu-Trp showed greater resistance to enzymatic breakdown in Caco-2 homogenates and higher apparent permeability, and one conjugate released the parent dipeptide after crossing Caco-2 monolayers. The conjugates showed no red blood cell toxicity in a hemolysis assay.^[2]

Because Glu-Trp isomers behave differently in experiments, researchers typically confirm identity and stereochemistry with HPLC and mass spectrometry data on a certificate of analysis.

Regulatory and Research Status

Thymogen (oglufanide) is not approved by the US Food and Drug Administration and is handled as a research compound in the United States. Its published record is small and concentrated in gerontology and experimental medicine journals, alongside a few chemistry and drug-delivery papers.

Key gaps remain. The abstracts reviewed here contain no randomized human trials, no defined receptor or binding target, and limited pharmacokinetic data beyond cell-based permeability work. The rat lifespan and tumor findings come from a single study and have not been confirmed in independent replications within this source set.^[1]

Because isomers of Glu-Trp behave differently in experimental systems, researchers working with the compound typically confirm that material is the L-L, alpha-linked form.^[3] Results reported for the sodium salt or acylated and D-alanine analogs should not be treated as interchangeable with the free dipeptide.